Distinctive exercise-induced inflammatory response and exerkine induction in skeletal muscle of people with type 2 diabetesShow others and affiliations
2022 (English)In: Science Advances, E-ISSN 2375-2548, Vol. 8, no 36, article id eabo3192Article in journal (Refereed) Published
Abstract [en]
Mechanistic insights into the molecular events by which exercise enhances the skeletal muscle phenotype are lacking, particularly in the context of type 2 diabetes. Here, we unravel a fundamental role for exercise-responsive cytokines (exerkines) on skeletal muscle development and growth in individuals with normal glucose tolerance or type 2 diabetes. Acute exercise triggered an inflammatory response in skeletal muscle, concomitant with an infiltration of immune cells. These exercise effects were potentiated in type 2 diabetes. In response to contraction or hypoxia, cytokines were mainly produced by endothelial cells and macrophages. The chemokine CXCL12 was induced by hypoxia in endothelial cells, as well as by conditioned medium from contracted myotubes in macrophages. We found that CXCL12 was associated with skeletal muscle remodeling after exercise and differentiation of cultured muscle. Collectively, acute aerobic exercise mounts a noncanonical inflammatory response, with an atypical production of exerkines, which is potentiated in type 2 diabetes.
Place, publisher, year, edition, pages
NLM (Medline) , 2022. Vol. 8, no 36, article id eabo3192
National Category
Physiology and Anatomy
Identifiers
URN: urn:nbn:se:umu:diva-199460DOI: 10.1126/sciadv.abo3192ISI: 000911968500015PubMedID: 36070371Scopus ID: 2-s2.0-85137461286OAI: oai:DiVA.org:umu-199460DiVA, id: diva2:1698963
Funder
Novo Nordisk, 17OC0030088Knut and Alice Wallenberg Foundation, 2018.0094Diabetesfonden, 2018-357Swedish Research Council, 2015-00165Swedish National Centre for Research in Sports, P2019-0140Swedish National Centre for Research in Sports, P2020-0064AstraZeneca, 2014-2019Novo Nordisk, 21SA0072747Swedish Heart Lung Foundation, 2017-0669Swedish Heart Lung Foundation, 2020-0627Diabetesfonden, 2018-336Novo Nordisk, 20SA00641442022-09-262022-09-262025-02-10Bibliographically approved